CRO expert in cardiac safety pharmacology
Safety Pharmacology defined in guideline ICH S7A aims to assess potential adverse effects of a test substance on vital functions (cardiovascular, respiratory and central nervous system are considered as the vital organ systems that should be studied in the core battery). The subsequent ICH S7B focused on the assessment of the effects of pharmaceuticals on ventricular repolarization and proarrhythmic risk.
Want to derisk your compound at an early stage?
Need help when selecting your compounds at a preclinical satge?
Need to determine early compounds able to induce QT prolongation?
PhysioStim has the relevant expertise to help you
Since 2000, PhysioStim – one of the European’s most reliable CRO (Contract Research Organisation) – has never ceased to improve its expertise in cardiac safety pharmacology. Indeed, PhysioStim’s experts offer electrophysiological studies, preclinical resources as well as their dedicated expertise in answering ICH S7A and S7B guidelines in accordance with GLPs (Good Laboratory Practices). PhysioStim therefore offers a wide range of services and consequently improves the quality of work.
Safety Studies Basics :
- Scientifically valid methods to be used
- Safety pharmacological studies to be performed by a specialized unit working under GLP conditions